Capital/Financing Update • Sep 18, 2014
Capital/Financing Update
Open in ViewerOpens in native device viewer
News Details
Corporate | 18 September 2014 08:02
WILEX AG: UCB waives repayment of shareholder loan to WILEX
WILEX AG / Key word(s): Miscellaneous
18.09.2014 / 08:02
PRESS RELEASE
UCB waives repayment of shareholder loan to WILEX
Munich, Germany, 18 September 2014 – WILEX AG (ISIN DE000A11QVV0 / WL6 / FSE) today announced that the shareholder UCB Pharma S.A. waived its claim for repayment of the shareholder loan to WILEX in the amount of 2.5 million Euro as well as interest of 100,000 Euro accrued in 2014.
In accordance with the termination of the collaboration in May 2014, a precondition was the transfer to UCB of the product candidates (a MEK and a PI3K inhibitor as well as three early stage antibody programmes) including all received rights thereto, development data and documentation as well as intellectual property. The declaration of the waiver with effective date 30 August 2014 was mutually signed and accepted.
Dr Jan Schmidt-Brand, CEO and CFO of WILEX AG, commented: “The waiver is an important step for us to offset the associated financial risk. Amongst the cost reduction measurements initiated in January and ongoing partnering activities, this is a significant milestone for this year.”
About WILEX
WILEX AG is a biopharmaceutical company based in Munich, Germany. Focused on oncology, the Company’s portfolio includes diagnostic and therapeutic product candidates for the specific detection and targeted treatment of various types of cancer based on antibodies. Our aim is out-licensing these clinical projects. The subsidiary Heidelberg Pharma GmbH offers preclinical contract research services and an antibody drug conjugate (ADC) technology platform. Our customers and partners include leading international pharmaceutical companies. More information is available at www.wilex.com .
| Company contact WILEX AG Sylvia Wimmer Tel.: +49 (0)89-41 31 38-29 Email: investors[at]wilex.com Grillparzerstr. 10, 81675 Munich, Germany |
IR/PR support MC Services AG Katja Arnold (CIRO) Executive Director Tel.: +49-89-210 228-40 Email: katja.arnold[at]mc-services.eu |
This communication contains certain forward-looking statements relating to the Company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “will”, “should”, “future”, “potential” or similar expressions or by a general discussion of the Company’s strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial position, earnings, achievements, or industry results, to be materially different from any future results, earnings or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.
18.09.2014 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
| Language: | English |
| Company: | WILEX AG |
| Grillparzerstr. 10 | |
| 81675 München | |
| Germany | |
| Phone: | +49 (0)89 41 31 38 – 0 |
| Fax: | +49 (0)89 41 31 38 – 99 |
| E-mail: | [email protected] |
| Internet: | www.wilex.com |
| ISIN: | DE000A11QVV0 |
| WKN: | A11QVV |
| Listed: | Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, München, Stuttgart |
| End of News | DGAP News-Service |
| - - - |
| 287420 18.09.2014 |
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.